BECN1 and neoplasm: Estimated tumor volume (Fig 5A), daily tumor growth (Fig 5B) and the tumor weight (Fig 5C) were most significantly inhibited in TW-37-treated Beclin-1-silenced tumor group (“shBec-1+TW-37”).